K. Mross

6.5k total citations
148 papers, 5.2k citations indexed

About

K. Mross is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, K. Mross has authored 148 papers receiving a total of 5.2k indexed citations (citations by other indexed papers that have themselves been cited), including 101 papers in Oncology, 37 papers in Molecular Biology and 29 papers in Pulmonary and Respiratory Medicine. Recurrent topics in K. Mross's work include Cancer Treatment and Pharmacology (61 papers), Chemotherapy-induced cardiotoxicity and mitigation (21 papers) and Colorectal Cancer Treatments and Studies (20 papers). K. Mross is often cited by papers focused on Cancer Treatment and Pharmacology (61 papers), Chemotherapy-induced cardiotoxicity and mitigation (21 papers) and Colorectal Cancer Treatments and Studies (20 papers). K. Mross collaborates with scholars based in Germany, Netherlands and United States. K. Mross's co-authors include Clemens Unger, Alex Sparreboom, Stephan Mielke, Annette Frost, Simone Steinbild, Michael Medinger, Joachim Drevs, Dirk Behringer, M. E. Scheulen and Martin Büchert and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

K. Mross

145 papers receiving 5.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
K. Mross Germany 37 3.1k 2.1k 1.0k 606 395 148 5.2k
M. E. Scheulen Germany 36 2.6k 0.8× 2.3k 1.1× 1.2k 1.1× 734 1.2× 390 1.0× 178 5.5k
Érick Gamelin France 42 4.2k 1.4× 1.7k 0.8× 1.0k 1.0× 476 0.8× 512 1.3× 138 6.3k
Guido Bocci Italy 42 2.6k 0.8× 2.4k 1.1× 1.0k 1.0× 1.2k 2.0× 317 0.8× 206 5.8k
Ferry A.L.M. Eskens Netherlands 43 2.9k 0.9× 2.6k 1.2× 1.5k 1.4× 1.2k 2.0× 694 1.8× 161 6.4k
Carolyn D. Britten United States 36 3.0k 1.0× 2.4k 1.2× 1.5k 1.4× 624 1.0× 417 1.1× 96 5.6k
Anderson J. Ryan United Kingdom 42 2.9k 1.0× 3.9k 1.8× 1.4k 1.3× 1.5k 2.4× 289 0.7× 159 7.4k
Shivaani Kummar United States 47 3.5k 1.1× 3.3k 1.6× 1.5k 1.4× 1.3k 2.1× 223 0.6× 296 7.0k
Kenji Kawada Japan 46 4.1k 1.3× 2.4k 1.1× 1.1k 1.0× 1.3k 2.2× 215 0.5× 238 7.7k
Michelle A. Rudek United States 48 2.5k 0.8× 3.8k 1.8× 1.0k 1.0× 1.2k 1.9× 142 0.4× 239 7.2k
Chris H. Takimoto United States 45 4.8k 1.6× 3.6k 1.7× 2.5k 2.4× 859 1.4× 314 0.8× 193 8.9k

Countries citing papers authored by K. Mross

Since Specialization
Citations

This map shows the geographic impact of K. Mross's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K. Mross with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K. Mross more than expected).

Fields of papers citing papers by K. Mross

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K. Mross. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K. Mross. The network helps show where K. Mross may publish in the future.

Co-authorship network of co-authors of K. Mross

This figure shows the co-authorship network connecting the top 25 collaborators of K. Mross. A scholar is included among the top collaborators of K. Mross based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K. Mross. K. Mross is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mross, K., Heike Richly, Richard Fischer, et al.. (2013). First-in-Human Phase I Study of PRS-050 (Angiocal), an Anticalin Targeting and Antagonizing VEGF-A, in Patients with Advanced Solid Tumors. PLoS ONE. 8(12). e83232–e83232. 41 indexed citations
2.
Mross, K., Annette Frost, Simone Steinbild, et al.. (2012). A Phase I Dose–Escalation Study of Regorafenib (BAY 73–4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors. Clinical Cancer Research. 18(9). 2658–2667. 262 indexed citations
3.
Mross, K.. (2012). Bevacizumab — eine endlose Geschichte. 15(8). 10–11.
4.
Fasol, Ulrike, Annette Frost, Martin Büchert, et al.. (2011). Vascular and pharmacokinetic effects of EndoTAG-1 in patients with advanced cancer and liver metastasis. Annals of Oncology. 23(4). 1030–1036. 79 indexed citations
5.
Steinbild, Simone, Annette Frost, Brian Z. Ring, Clemens Unger, & K. Mross. (2009). Phase II Study with 3rd- or 4th-Line Bendamustine (Flat Dose) Therapy in Patients with Metastatic Breast Cancer. Onkologie. 32(8-9). 488–492. 1 indexed citations
6.
Henningsson, Anja, Sharon Marsh, Walter J. Loos, et al.. (2005). Association ofCYP2C8, CYP3A4, CYP3A5, andABCB1Polymorphisms with the Pharmacokinetics of Paclitaxel. Clinical Cancer Research. 11(22). 8097–8104. 151 indexed citations
7.
Mross, K., Annette Frost, Ralph Strecker, et al.. (2005). A clinical phase I, pharmacokinetic (PK), and pharmacodynamic study of twice daily BIBF 1120 in advanced cancer patients. Journal of Clinical Oncology. 23(16_suppl). 3031–3031. 19 indexed citations
8.
Azémar, Marc, S. Djahansouzi, Elke Jäger, et al.. (2003). Regression of Cutaneous Tumor Lesions in Patients Intratumorally Injected with a Recombinant Single-chain Antibody-toxin Targeted to ErbB2/HER2. Breast Cancer Research and Treatment. 82(3). 155–164. 69 indexed citations
9.
Mielke, Stephan, K. Mross, Thomas Alexander Gerds, et al.. (2003). Comparative neurotoxicity of weekly non-break paclitaxel infusions over 1 versus 3 h. Anti-Cancer Drugs. 14(10). 785–792. 31 indexed citations
10.
11.
12.
13.
Herrmann, Richard, K. Mross, Ulrich R. Kleeberg, et al.. (1995). 4′-lodo-4′-Deoxydoxorubicin (IDX) in Colorectal Cancer – A Multicenter Phase II Study. Oncology Research and Treatment. 18(1). 28–30. 1 indexed citations
14.
Thürlimann, Beat, Nicolaus Kröger, K. Mross, et al.. (1995). Dexverapamil to overcome epirubicin resistance in advanced breast cancer. Journal of Cancer Research and Clinical Oncology. 121(S3). R3–R6. 10 indexed citations
15.
Kraus, T., et al.. (1993). Pharmacokinetics of Doxorubicin in the Heparinized Perfusate during Isolated Hyperthermic Limb Perfusion. Oncology Research and Treatment. 16(1). 16–21. 3 indexed citations
16.
Mross, K., et al.. (1992). Pharmacokinetic and Pharmacodynamic Study with Lobaplatin (D-19466), a New Platinum Complex, after Bolus Administration. Oncology Research and Treatment. 15(2). 139–146. 11 indexed citations
17.
Mross, K., et al.. (1992). Tissue disposition and plasma concentrations of idarubicin after intravesical therapy in patients with bladder tumors. Cancer Chemotherapy and Pharmacology. 29(6). 490–494. 5 indexed citations
18.
Mross, K., et al.. (1990). Phase I/II study of intravesical epirubicin in patients with carcinoma in situ of the bladder.. PubMed. 350. 41–59. 5 indexed citations
19.
Queißer, W., P. Preusser, K. Mross, et al.. (1990). Phase II Evaluation of Carboplatin in Advanced Esophageal Carcinoma. Oncology Research and Treatment. 13(3). 190–193. 9 indexed citations
20.
Vijgh, W. J. F. van der, et al.. (1988). Morphometric study of myocardial changes during doxorubicin-induced cardiomyopathy in mice. European Journal of Cancer and Clinical Oncology. 24(10). 1603–1608. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by M. E. Scheulen Breakdown of academic impact, for papers by Érick Gamelin Breakdown of academic impact, for papers by Guido Bocci Breakdown of academic impact, for papers by Ferry A.L.M. Eskens Breakdown of academic impact, for papers by Carolyn D. Britten Breakdown of academic impact, for papers by Anderson J. Ryan Breakdown of academic impact, for papers by Shivaani Kummar Breakdown of academic impact, for papers by Kenji Kawada Breakdown of academic impact, for papers by Michelle A. Rudek Breakdown of academic impact, for papers by Chris H. Takimoto
Rankless by CCL
2026